CNR1 and obesity disorder: Another study supported these findings and indicated that solely peripherally active CB1 inverse agonists/antagonists had therapeutic potential in obesity because of their high efficacy in normalizing the related metabolic abnormalities, including insulin resistance and fatty liver [64].